Quinazoline derivatives as anticancer drugs: a patent review (2011-present)

Ravez, Severine; Castillo-Aguilera, Omar; Depreux, Patrick; Goossens, Laurence

Type de document :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.1517/13543776.2015.1039512

PMID :

25910402

URL permanente :

http://hdl.handle.net/20.500.12210/4414

Titre :

Quinazoline derivatives as anticancer drugs: a patent review (2011-present)

Auteur(s) :

Ravez, Severine [Auteur]

Lille Neurosciences & Cognition (LilNCog) - U 1172
Castillo-Aguilera, Omar [Auteur]
Institut de Chimie Pharmaceutique Albert Lespagnol [ICPAL]
Depreux, Patrick [Auteur]

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - EA 7365
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Goossens, Laurence [Auteur]

495476|||Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]

Titre de la revue :

Expert Opinion on Therapeutic Patents

Nom court de la revue :

Expert Opin. Ther. Patents

Numéro :

Pagination :

789-804

Date de publication :

2015

ISSN :

1354-3776

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Introduction: Quinazoline is one of the most studied moieties in medicinal chemistry due to the wide range of biological properties such as the anticancer, antibacterial, anti-inflammatory, antimalarial and antihypertensive ...
Lire la suite >Introduction: Quinazoline is one of the most studied moieties in medicinal chemistry due to the wide range of biological properties such as the anticancer, antibacterial, anti-inflammatory, antimalarial and antihypertensive activities. During the past decades, several patents and articles have been published in international peer-reviewed literature regarding the discovery and development of original and promising quinazoline derivatives for cancer treatment. Although quinazolines are well known to inhibit EGFR, there is also a large panel of other therapeutic protein targets. Areas covered: This review summarized the new patents and articles published about quinazoline derivatives as anticancer drugs since 2011. Expert opinion: Since 2011, a lot of quinazoline compounds have shown EGFR inhibition. Unlike the first-generation EGFR inhibitors, they inhibit both wild-type and mutated EGFR. In recent years, a number of studies on quinazoline synthesis have been reported and used by several medicinal chemistry groups for better and easier development of new derivatives. Therefore, several patents have been approved for the use of quinazoline compounds as inhibitors of other kinases, histone deacetylase, Nox and some metabolic pathways. Because of the large number of proteins targeted, some high structural diversity is observed in patented quinazoline compounds. Due to the vast applications of quinazoline derivatives, development of novel quinazoline compounds as anticancer drugs remains a promising field.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille
Inserm

Collections :

Équipe(s) de recherche :

Modélisation biopharmaceutique et pharmacocinétique

Date de dépôt :

2019-02-26T17:09:48Z
2022-01-19T08:58:51Z

Numéro de version	Lien	Date de modification
2	20.500.12210/4414*	2022-01-19T08:24:20Z
1	20.500.12210/4414.1	2019-02-26T17:09:48Z

Quinazoline derivatives as anticancer ...

BibTeX

CSV

Excel

RIS

Historique des modifications

Quinazoline derivatives as anticancer ... BibTeX CSV Excel RIS

Historique des modifications

Quinazoline derivatives as anticancer ...

BibTeX

CSV

Excel

RIS